Sarcoidosis associated with vemurafenib

British Journal of Dermatology

Volumn 169, Issue 1, 2013, Pages 206-208

  Adam, A ^a,b   Thomas, L ^a,b   Bories, N ^a   Zaharia, D ^a,b   Balme, B ^a   Freymond, N ^a   Dalle, S ^a,b,c  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

BRAF; melanoma; sarcoidosis; vemurafenib

Indexed keywords

CORTICOSTEROID; HYDROXYCHLOROQUINE; VEMURAFENIB; INDOLE DERIVATIVE; SULFONAMIDE;

ADRENAL METASTASIS; ADULT; AGED; ARTHRALGIA; AXILLARY LYMPH NODE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CANCER THERAPY; CASE REPORT; CORTICOSTEROID THERAPY; DERMATITIS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; KIDNEY METASTASIS; LETTER; LIVEDO RETICULARIS; LUNG BIOPSY; LUNG METASTASIS; LUNG SARCOIDOSIS; LYMPH NODE METASTASIS; MALE; METASTATIC MELANOMA; NEUROIMAGING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SARCOIDOSIS; SENTINEL LYMPH NODE; SKIN BIOPSY; SKIN DEFECT; SKIN DISCOLORATION; TREATMENT RESPONSE; TUBERCULOSIS; UVEITIS; CHEMICALLY INDUCED; DRUG ERUPTIONS; MELANOMA; SKIN NEOPLASMS;

ADULT; AGED; DRUG ERUPTIONS; HUMANS; INDOLES; MALE; MELANOMA; SARCOIDOSIS; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84879951226     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12268     Document Type: Letter

References (5)

1. Flaherty KT, Puzanov I, Kim KB, et al,. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
2. Dalle S, Poulalhon N, Thomas L,. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 365: 1448-9; author reply 50.
3. Sinha R, Edmonds K, Newton-Bishop JA, et al,. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167: 987-94.
4. Wilgenhof S, Morlion V, Seghers AC, et al,. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res 2012; 32: 1355-9.
5. Wancket LM, Frazier WJ, Liu Y,. Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci 2012; 90: 237-48.